反应详情

Following the procedure in Example 1, Step 6, 4-[3-(4-fluoro-phenoxy)-benzylidene]-piperidine hydrochloride (200 mg, 0.625 mmol) (Step 3) and phenyl benzo[c]isoxazol-3-ylcarbamate (175 mg, 0.688 mmol) were used to provide the title compound (275 mg). MS (APCI 10V) AP+ 444.2, 284.2, AP− 442.2; 1H NMR (400 MHz, CDCl3) δ ppm 2.46-2.52 (m, 2H) 2.57-2.63 (m, 2H) 3.56-3.62 (m, 2H) 3.66-3.72 (m, 2H) 6.39 (s, 1H) 6.78-6.87 (m, 2H) 6.91-6.96 (m, J=7.93, 1.25, 0.68, 0.57 Hz, 1H) 6.97-7.07 (m, 4H) 7.25-7.31 (m, 2H) 7.47 (dt, J=8.41, 0.77 Hz, 1H) 7.50-7.55 (m, 1H) 7.71 (s, 1H) 8.09 (d, J=7.90 Hz, 1H).